Phathom Pharmaceuticals, Inc. (PHAT) stock
PHATNasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.06−0.17 (-2.73%)
Close on Nov 13, 2026Market cap $492.63MP/E –Yield –
Phathom Pharmaceuticals gross margin
Gross margin is gross profit as a percentage of revenue.
Phathom Pharmaceuticals's gross margin for the twelve months ending Sep 30, 2026 was 80.7%. For fiscal 2025 it was 87.1%, against 85.6% the year before.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 87.1% | +1.5 |
| FY2024 | Dec 31, 2024 | 85.6% | +10.1 |
| FY2023 | Dec 31, 2023 | 75.5% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 78.3% | −9.2 |
| Q2 FY2026 | Jun 30, 2026 | 79.7% | −7.6 |
| Q1 FY2026 | Mar 31, 2026 | 79.4% | −7.5 |
| Q4 FY2025 | Dec 31, 2025 | 86.7% | −0.4 |
| Q3 FY2025 | Sep 30, 2025 | 87.5% | +1.9 |
| Q2 FY2025 | Jun 30, 2025 | 87.2% | +6.0 |
| Q1 FY2025 | Mar 31, 2025 | 86.9% | +9.2 |
| Q4 FY2024 | Dec 31, 2024 | 87.1% | +11.6 |
| Q3 FY2024 | Sep 30, 2024 | 85.6% | – |
| Q2 FY2024 | Jun 30, 2024 | 81.2% | – |
| Q1 FY2024 | Mar 31, 2024 | 77.7% | – |
| Q4 FY2023 | Dec 31, 2023 | 75.5% | – |
See a number that looks wrong?